SER logo

SERINA THERAPEUTICS INC.

SERNYSE AMERICAN
πŸ† #4398 by market capEarnings Mar 30US Equity
$1.12β–Ό $0.08 (βˆ’6.67%)
Market closed Β· at close
πŸ””
Track SER
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 6.7%
7dβ–Ό 23.5%
14dβ–Ό 17.9%
30dβ–Ό 36.4%
ytdβ–Ό 39.8%
1yβ–Ό 71.6%
🏦Market Cap
$28M
Small Cap
πŸ“ˆRevenue Growth (YoY)
β€”
πŸ“ŠGross Margin
65.1%
High
πŸ’΅FCF Margin
β€”
βš–οΈP/S Ratio
206.7x
Expensive
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$1.06 – $1.23
52-Week Range
$1.06 – $4.26
Volume (shares)
62,151
Avg Volume (shares)
β€”
Shares Outstanding
25.4M
Next Earnings
2027-03-30

Fundamentals Snapshot

Annual Revenue
β€”
Last Q Revenue
$125,000
P/E Ratio
β€”
P/S Ratio
206.7x
EPS (TTM)
$-1.14
Dividend Yield
β€”
Dilution (1yr)
βˆ’5.2%
SER logo

SERINA THERAPEUTICS INC.

SER
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0β–Ό βˆ’100.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
-246.4%β–Ό βˆ’353.7% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$24Mβ–² +40.9% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$18Mβ–² +5.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
10.2Mβ–Ό βˆ’5.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$86Kβ–Ό βˆ’$3M YoY
StockOtter Β· stockotter.space

About SERINA THERAPEUTICS INC.

Serina Therapeutics, Inc., a biotechnology firm, focuses on creating pharmaceutical treatments for neurological conditions and pain. Its primary investigational drug, SER 252, is a POZ conjugate intended for managing Parkinson's disease. The company is also developing SER 227 for prolonged pain relief, SER 214, another candidate for Parkinson's disease, and SER 228 to treat epilepsy. Beyond these, Serina Therapeutics leverages its POZ technology in producing ribonucleic acid (RNA) vaccines delivered via lipid nanoparticles for combating infectious diseases. This company was established in 2006 and is headquartered in Huntsville, Alabama.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100

Analyst Ratings

β“˜
Consensus
Buy
6 analysts
Strong Buy2
Buy3
Hold1
Sell0
Strong Sell0
Ratings as of Nov 2026

Latest News & Updates

GlobeNewsWireΒ·10d ago

Serina Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates

– Independent Safety Monitoring Committee recommended advancement of SER-252 in Parkinson's disease to Cohort 2Β  – Dosing initiated in Cohort 2 of the registrational study ; topline single-ascending-dose data expected in

GlobeNewsWireΒ·18d ago

Seres Therapeutics Reports Third Quarter 2026 Financial Results and Announces Plans for Advancing Development of SER-155 To Prevent Immune Checkpoint Inhibitor-Related Enterocolitis (irEC)

Prevention approach aims to keep patients on immune checkpoint inhibitor (ICI) therapy and avoid immunosuppressive irEC treatments, representing an additional broad therapeutic opportunity for SER-155 Seres expects to su

GlobeNewsWireΒ·19d ago

Seres Therapeutics Announces Publication of SER-155 Phase 1b Results in Nature Medicine Showing Reduced Bloodstream Infections in Allogeneic Hematopoietic Cell Transplantation Recipients

Peer-reviewed publication reports a 77% relative risk reduction in bloodstream infections and significantly lower systemic antibiotic exposure with SER-155 compared with placebo Translational data from the study support

Business WireΒ·27d ago

Custom Truck One Source, Inc. Reports Record Third Quarter 2026 Results and Increases Full Year 2026 Adjusted EBITDA and SER Revenue Guidance

KANSAS CITY, Mo.--(BUSINESS WIRE)--Custom Truck One Source, Inc. (NYSE: CTOS), a leading provider of specialty equipment to the electric utility, telecom, rail, forestry, waste management and other infrastructure-related

GlobeNewsWireΒ·Oct 15

Seres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026

Novel oral liquid formulationΒ  of SER-428 is designed for patients who cannot take oral capsules, including critically ill patients receiving nutrition via feeding tube

GlobeNewsWireΒ·Sep 23

Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar EventΒ "A New Approach to Advanced Parkinson's Disease: Serina Discusses SER-252's Clinical Progress"

Featuring Serina Therapeutics' CEO - Thursday, September 24, 2026 10M people in the world currently living with Parkinson's disease with no major clinical advances in 50+ years Meet with Serina's CEO Steven Ledger Regist